EUCTR2005-004737-17-IT进行中（未招募）不适用
Evaluation of the Efficacy of Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelodysplastic Syndrome - DARB-MDS
AZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI0 个研究点目标入组 54 人开始时间: 2005年10月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Low or Intermediate-1 risk MDS. Hemoglobin < 11.0 g/dL. No other evidence of causes of anemia. Adequate hepatic and renal function. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Secondary MDS or evolving from prior hematological malignancy. Intermediate-2 or High risk MDS. Uncontrolled hypertension (systolic blood pressure > 170 mmHg, diastolic blood pressure > 100 mmHg). Angina, uncontrolled arrythmia or heart failure. Previous thrombo-embolic events. Untreated thrombophilic abnormalities. Known hypersensitivity to rHuEPO.
研究者
相似试验
已完成
不适用
The effect of intervention with darbepoetin alfa on progression of renal decline[chronic renal failure?] in renal anaemia patients with chronic kidney disease not on dialysis.renal anaemia patients with chronic kidney disease not on dialysisJPRN-UMIN000006963Division of Nephrology,Department of Internal Medicine,Juntendo University Faculty of Medicine200
尚未招募
2 期
Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancerCancer - BreastBreast CancerACTRN12605000731695Mater Adult hospital30
已完成
不适用
Analysis on response to darbepoetin alfa in patients with low risk myelodysplastic syndromesJPRN-UMIN000022185Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu85
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving ChemotherapyEUCTR2004-001417-33-ITAMGE
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-SEAmgen Inc400